| 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-088 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 公司将持续关注本员工持股计划的实施进展情况，并按照相关法律法规的规 定及时履行信息披露义务。 特此公告。 广西柳药集团股份有限公司董事会 根据《关于上市公司实施员工持股计划试点的指导意见》《上海证券交易所 上市公司自律监管指引第 1 号——规范运作》等相关规定，现将本员工持股计划 的实施进展情况公告如下： 根据参与对象实际认购和最终缴款的审验结果，本员工持股计划首次受让部 分实际参与认购的员工共计 52 人，最终认购份额为 14,405,400 份，认购份额对 应的股份数量为 1,590,000 股，最终缴纳的认购资金总额为 14,405,400.00 元，股 份来源为公司回购专用证券账户回购的公司 A 股普通股股票。 2025 年 10 月 17 日，公司收到中国证券登记结算有限责任公司出具的《证 券过户登记确认书》，公司回购专用证券账户中所持有的 1,590,000 股公司股份已 于 2025 ...

Summary of Key Points Core Viewpoint - The company has provided guarantees totaling 23,146.43 million yuan to its subsidiaries to support their operational and business development needs, while also releasing guarantees amounting to 33,759.93 million yuan as of September 2025 [1][5]. Group 1: Guarantee Overview - The company and its subsidiaries have applied for a total of 23,146.43 million yuan in new guarantees as of September 2025 [1]. - The total amount of guarantees provided by the company and its subsidiaries is 247,002.10 million yuan, which accounts for 32.40% of the company's most recent audited net assets [5]. Group 2: Internal Decision-Making Process - The company held a board meeting on March 26, 2025, and an annual shareholders' meeting on April 18, 2025, to approve the guarantee limit for 2025, allowing for a total guarantee amount not exceeding 7 billion yuan [1][4]. Group 3: Necessity and Reasonableness of Guarantees - The guarantees are deemed necessary and reasonable to meet the funding needs for production and business development, aligning with the company's overall interests and development strategy [3][4]. - The company maintains absolute control over the operations and financial conditions of the guaranteed subsidiaries, ensuring that the risks associated with the guarantees are manageable [3][4]. Group 4: Board of Directors' Opinion - The board believes that providing guarantees to subsidiaries is a rational decision based on business development needs and financing requirements, which will facilitate the normal operation of the company's main business and enhance future economic benefits [4].

Core Points - The company and its subsidiaries provided a total guarantee of 231.46 million yuan to meet operational and business development needs, while releasing guarantees totaling 337.60 million yuan in September 2025 [2][4] - The board of directors approved a total guarantee limit of up to 7 billion yuan for the year 2025, allowing for inter-company guarantees within the approved limit [4][7] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amounted to 2.47 billion yuan, representing 32.40% of the latest audited net assets [8] Guarantee Details - The guarantees provided are classified as routine guarantees, with specific amounts detailed for each subsidiary [4][5] - The guarantees are primarily aimed at satisfying the funding needs for production and business development, aligning with the company's overall interests and strategic goals [6][7] - The company maintains absolute control over the operations and financial conditions of the guaranteed subsidiaries, ensuring manageable risk levels [6][7] Board's Opinion - The board believes that providing guarantees to subsidiaries is a reasonable prediction based on business development needs and financing requirements, which will benefit the company's main operations and enhance future economic benefits [7] - The financial stability and creditworthiness of the guaranteed entities are affirmed, with the company capable of effectively controlling financial risks [7] Guarantee Agreement - The guarantees are structured as joint liability guarantees with a term of three years from the debt performance deadline [10] - The total guarantee amount is 231.46 million yuan, reflecting the company's commitment to supporting its subsidiaries [10]

| 证券代码：603368 | 证券简称：柳药集团 公告编号：2025-087 | | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | 广西柳药集团股份有限公司 关于公司及下属控股子公司提供担保的进展公告 担保对象及基本情况 | | 被担保人名称 | 万元 | | 广西柳药集团股份有限公司（简称"公司"） | | --- | --- | --- | --- | --- | | | 本次担保金额 | 11,621.83 | | | | 担保 对象一 | 实际为其提供的担保余额 | 27,152.66 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | □否 | 不适用：_________ | | | 本次担保是否有反担保 | □是 | 否 | 不适用：_________ | | 担保 | 被担保人名称 | | | 广西南宁柳药药业有限公司（简称"南宁柳药"） | | | 本次担保金额 | 6,524.61 | 万元 | | | 对象二 | 实际为其提供的担保余额 | 124,874.45 | | 万元（含本次） | | | 是否在前期预计额度内 | 是 | ...

10月13日，柳药集团在互动平台向投资者表示，公司针对中老年人及特殊群体深入实施慢病管理项目， 应用AI问诊等数字化健康服务，形成差异化优势，实现药店从"药品销售"向"健康服务"的转型升级。同 时发挥自营互联网医院优势，开展线上诊疗、慢病续方、健康咨询等服务，最终实现线上、线下诊疗服 务与零售药店专业购药服务、健康管理服务的对接，打造"互联网+医药+健康管理"一站式就医用药链 条，构建完整的"新零售"业态。2025年上半年，柳药集团实现营收103.01亿元，同比减少3.21%，实现 归母净利润4.29亿元，同比减少7.52%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ● 会议召开方式：上证路演中心网络互动 ● 问题征集方式：投资者可于2025年10月13日（星期一）至10月17日(星期五)16:00前登录上证路演中心 网站首页点击"提问预征集"栏目或通过公司邮箱lygf@lzyy.cn进行提问。公司将在2025年半年度业绩说 明会（以下简称"本次业绩说明会"）上对投资者普遍关注的问题进行回答。 广西柳药集团股份有限公司（以下简称"公司"）已于2025年8月29日在上海证券交易所网站 （http://www.sse.com.cn）披露《2025年半年度报告》，为便于广大投资者更全面深入地了解公司2025 年半年度的经营成果、财务状况，公司决定于2025年10月20日（星期一）15:00-16:00召开本次业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对2025年半年度经营成果及财务指标的具体情况与投资 者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍关注的公司经营业绩、战略规划、财务 状况等问题进行回答，欢迎广大投资者积极参与。 二、说明会召开的时间、地点及方式 ...

Core Insights - The pharmaceutical commercial sector saw a slight increase of 0.17% on October 10, with Guofa Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3897.03, down 0.94%, while the Shenzhen Component Index closed at 13355.42, down 2.7% [1] Stock Performance - Guofa Co., Ltd. (600538) closed at 5.85, up 4.28% with a trading volume of 178,800 shares and a transaction value of 103 million yuan [1] - Other notable gainers included Dajia Weikang (301126) up 1.89%, Yingte Group (000411) up 1.77%, and Liuyao Group (603368) up 1.75% [1] - Conversely, the sector also experienced declines, with Saily Medical (603716) down 4.51% and Jianfa Zhixin (301584) down 4.01% [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 161 million yuan from institutional investors, while retail investors saw a net inflow of 214 million yuan [2] - The data indicates that while institutional investors were pulling back, retail investors were actively buying into the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 27.32 million yuan from institutional investors, while it faced a net outflow of 32.58 million yuan from speculative funds [3] - Dajia Weikang (301126) saw a net inflow of 4.95 million yuan from institutional investors, but also faced outflows from speculative funds [3] - Guofa Co., Ltd. (600538) had a net inflow of 4.07 million yuan from institutional investors, indicating some level of interest despite the overall outflow trend [3]

重要内容提示： ● 问题征集方式：投资者可于2025年10月13日（星期一）至10月17日(星期 五)16:00前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 lygf@lzyy.cn进行提问。公司将在2025年半年度业绩说明会（以下简称"本次业 绩说明会"）上对投资者普遍关注的问题进行回答。 | 证券代码：603368 | 证券简称：柳药集团 | 公告编号：2025-086 | | --- | --- | --- | | 转债代码：113563 | 转债简称：柳药转债 | | 广西柳药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 三、参加人员 广西柳药集团股份有限公司（以下简称"公司"）已于2025年8月29日在上海 证券交易所网站（http://www.sse.com.cn）披露《2025年半年度报告》，为便于广 大投资者更全面深入地了解公司2025年半年度的经营成果、财务状况，公司决定 于2025年10月20日（星期一 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 301015 | 百洋医药 | 27.17 | -2.96% | 5.74万 | 1.58亿 | | 301584 | C建发致 | 28.15 | -2.90% | 21.71万 | 6.15亿 | | 600833 | 第一医药 | 13.38 | -2.76% | 8.11万 | 260'T | | 301126 | 达嘉维康 | 11.13 | -2.37% | 4.04万 | 4537.69万 | | 603108 | 润达医疗 | 15.70 | -1.88% | 19.17万 | 3.00亿 | | 000705 | 浙江震元 | 9.78 | -1.41% | 13.46万 | 1.31亿 | | 002462 | 章章点 | 13.69 | -0.58% | 4.41万 | 6013.33万 | | 300937 | 药易购 | 26.53 | -0.49% | 1.29万 | 3415.25万 | | 600538 | 国发股份 ...

格隆汇10月9日丨柳药集团(603368.SH)公布，截至2025年9月30日，公司通过集中竞价交易方式回购股 份数量为810.79万股，已回购股份占公司目前总股本的比例为2.04%，较上次回购进展公告披露数无变 化，回购成交的最高价为18.60元/股、最低价为17.83元/股，已支付的总金额为14,846.49万元（不含交 易费用）。 ...